Plaque Psoriasis
The MD Magazine Plaque Psoriasis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

10-Year Follow-up Study on Safety and Efficacy of Adalimumab
Study shows that adalimumab led to sustained clinical and functional responses in nearly one-third of treatment-refractory patients who completed 10 years of treatment. Patients with shorter disease duration achieved better outcomes, highlighting the need for early treatment.
Calling dermatology the study of the skin only begins to scratch the surface of the field. While environmental factors have been thoroughly looked at, advancements in technology are allowing doctors and researchers to look for deeper issues affecting their patients.
A recent review looked at the immunopathogenesis of psoriasis, identified key mediators of psoriatic plaques that are being targeted by new and emerging biologic therapies, and highlighted the latest efficacy and safety data from trials of these new agents.
Researchers are learning more about the safety and efficacy of anti-interleukin-17 and anti-interleukin-23 (IL-23) therapy, although there are several agents currently under investigation. Anti-TNF agents and IL agents target psoriatic inflammation through different pathways.
Successful preliminary trials revealed that treatment with a novel anti–interleukin-23 monoclonal antibody, guselkumab, (CNTO 1959/Janssen) was more effective at reducing the symptoms of plaque psoriasis than adalimumab.
Inflammatory chronic diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis bring many treatment challenges. Among them is the fact that biologic therapies for these diseases—particularly anti-TNF agents—while effective, can themselves bring reactivation of a latent tuberculosis infection.
Coming next from Medicare: the ICD-10 Obmudsman. Billing under the dreaded new International Classification of Diseases-10 (ICD-10) coding system will get a bit less onerous under a deal brokered between Medicare and the American Medical Association.

Most Popular

$vacMongoViewPlus$ $vAR$